Cosmo Pharmaceuticals

Cosmo Pharmaceuticals EBIT Margin

The EBIT Margin (Operating Margin) of Cosmo Pharmaceuticals (COPN.SW) as of Nov 4, 2026 is -10.00 %. In the previous year, EBIT Margin (Operating Margin) was 55.81 % — a change of -117.92% (lower).

EBIT Margin

-10.00 %

YoY

-117.92%

Last updated:

EBIT Margin (Operating Margin) of Cosmo Pharmaceuticals is 2025 -10.00 % . EBIT Margin (Operating Margin) of Cosmo Pharmaceuticals was 2024 55.81 % . It decreases by -117.92% lower compared to the previous year.

For Cosmo Pharmaceuticals, the operating (EBIT) margin of -10.0% is down versus 26.9% a few years ago.

The Cosmo Pharmaceuticals EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
-25.33 EUR
Jan 1, 2019
-21.70 EUR
Jan 1, 2020
11.33 EUR
Jan 1, 2021
26.91 EUR
Jan 1, 2022
27.48 EUR
Jan 1, 2023
6.62 EUR
Jan 1, 2024
55.81 EUR
Jan 1, 2025
-10.00 EUR
The Cosmo Pharmaceuticals EBIT Margin history
YEAREBIT MarginYoY
-10.00 %-117.92%
55.81 %+742.44%
6.62 %-75.90%
27.48 %+2.14%
26.91 %+137.51%
11.33 %-152.22%
-21.70 %-14.35%
-25.33 %+9.92%
-23.05 %-174.24%
31.04 %-92.48%
412.99 %+1,379.76%
27.91 %+12,059.55%
0.23 %-48.34%
0.44 %+49.79%
0.30 %+75.64%
0.17 %-21.39%
0.21 %-41.51%
0.37 %+3,540.12%
0.01 %-109.62%
-0.10 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cosmo Pharmaceuticals Stock analysis

What does Cosmo Pharmaceuticals do? Cosmo Pharmaceuticals NV is an international pharmaceutical company based in Dublin, Ireland. The company focuses on developing innovative drugs for various diseases, including gastroenterology, oncology, and infectious diseases. The history of Cosmo Pharmaceuticals dates back to 1997 when it was founded by Dr. Mauro Ajani in Italy. Since then, the company has undergone impressive development and is now listed on the SIX Swiss Exchange. In 2020, the company moved from Italy to Ireland to strengthen its international presence. Cosmo Pharmaceuticals' business model is based on creating patented innovations and technologies in drug development. The company works closely with other companies and research institutions to introduce a wide range of products that benefit both patients and healthcare providers. The main source of income for Cosmo Pharmaceuticals is the licenses they grant for their products, as well as the manufacturing and sale of their own products. Cosmo Pharmaceuticals operates three main business areas: Human, Veterinary, and Proprietary. The Human division specializes in the development of drugs for humans. The company's products are available worldwide, including in the United States, Europe, Japan, and China. In the field of gastroenterology, Cosmo Pharmaceuticals is one of the leading companies on the market and has developed several products to treat gastrointestinal problems and other gastrointestinal diseases. The Veterinary division of Cosmo Pharmaceuticals specializes in the development of animal medicines. The company works with veterinarians and pet owners to bring products to market that help animals stay healthy or recover. Cosmo Pharmaceuticals offers several products tailored to the specific needs of animals, including Ballistol Animal, used for skin and fur care, and Otilonium Bromide, used for digestive disorders in horses. The Proprietary division is the third major business area of Cosmo Pharmaceuticals. This is a segment that manufactures its own products and sells them directly to patients or institutions. The company's products include Eleview, used in endoscopy to improve visibility of the gastrointestinal mucosa. Cosmo Pharmaceuticals is an innovative company focused on the development of drugs that can help improve patients' lives. The company collaborates closely with other companies and research institutions to leverage the latest technologies and developments in the industry. With its broad portfolio of products in the field of gastroenterology, oncology, and infectious diseases, the company has a strong presence in the industry and actively advocates for more people to have access to the best medical treatments. Cosmo Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cosmo Pharmaceuticals stock

EBIT Margin (Operating Margin) of Cosmo Pharmaceuticals is -10.00 % in 2025.

EBIT Margin (Operating Margin) of Cosmo Pharmaceuticals changed from 55.81 % to -10.00 %, representing a -117.92% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Cosmo Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Cosmo Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Cosmo Pharmaceuticals

All Key Metrics — Cosmo Pharmaceuticals